PMID- 37185742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230517
IS  - 1467-3045 (Electronic)
IS  - 1467-3037 (Print)
IS  - 1467-3037 (Linking)
VI  - 45
IP  - 4
DP  - 2023 Apr 11
TI  - The Involvement of Hypoxia in the Response of Neuroblastoma Cells to the Exposure 
      of Atorvastatin.
PG  - 3333-3346
LID - 10.3390/cimb45040218 [doi]
AB  - Cancer is a set of complex diseases, being one of the leading causes of death 
      worldwide. Despite a lot of research on the molecular pathways and effective 
      treatments, there are still huge gaps. Indeed, the development of new anti-cancer 
      drugs is a complex process. To face this problem, drug repurposing is being 
      increasingly applied. This approach aims to identify new indications for already 
      approved drugs. In this regard, statins (clinically used for reducing cholesterol 
      levels) are reported to induce anti-cancer effects, particularly by inducing 
      apoptosis and altering the tumor microenvironment. Atorvastatin is a type of 
      statin with several potentialities as an anti-cancer agent, supported by several 
      studies. Our study aimed to explore the effect of this drug in SH-SY5Y human 
      neuroblastoma cells. Additionally, we also aimed to understand how this drug acts 
      under hypoxia and the inhibition of hypoxia-inducible factor-1 (HIF-1). For that 
      purpose, we assessed cellular viability/morphology after exposure to different 
      concentrations of atorvastatin, with or without chemically induced hypoxia with 
      chloride cobalt (CoCl(2)) and with or without echinomycin (HIF-1alpha inhibitor). Our 
      results supported the cytotoxic effects of atorvastatin. Additionally, we also 
      revealed that besides these effects, under hypoxia, this drug induced 
      proliferation of the neuroblastoma cells, supporting the importance of different 
      stimuli and environment on the effect of drugs on cancer cells.
FAU - Correia, Ana Salome
AU  - Correia AS
AUID- ORCID: 0000-0002-8231-1560
AD  - OncoPharma Research Group, Center for Health Technology and Services Research 
      (CINTESIS), Rua Doutor Placido da Costa, 4200-450 Porto, Portugal.
AD  - Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua 
      de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
AD  - CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor 
      Hernani Monteiro, 4200-319 Porto, Portugal.
FAU - Marques, Lara
AU  - Marques L
AUID- ORCID: 0000-0002-7003-4957
AD  - OncoPharma Research Group, Center for Health Technology and Services Research 
      (CINTESIS), Rua Doutor Placido da Costa, 4200-450 Porto, Portugal.
AD  - CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor 
      Hernani Monteiro, 4200-319 Porto, Portugal.
FAU - Vale, Nuno
AU  - Vale N
AUID- ORCID: 0000-0002-1283-1042
AD  - OncoPharma Research Group, Center for Health Technology and Services Research 
      (CINTESIS), Rua Doutor Placido da Costa, 4200-450 Porto, Portugal.
AD  - CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor 
      Hernani Monteiro, 4200-319 Porto, Portugal.
AD  - Department of Community Medicine, Information and Health Decision Sciences 
      (MEDCIDS), Faculty of Medicine, University of Porto, Alameda Professor Hernani 
      Monteiro, 4200-319 Porto, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20230411
PL  - Switzerland
TA  - Curr Issues Mol Biol
JT  - Current issues in molecular biology
JID - 100931761
PMC - PMC10137104
OTO - NOTNLM
OT  - atorvastatin
OT  - drug repurposing
OT  - echinomycin
OT  - hypoxia-inducible factor-1
OT  - neuroblastoma cells
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/15 19:12
MHDA- 2023/05/15 19:13
PMCR- 2023/04/11
CRDT- 2023/05/15 13:46
PHST- 2023/03/02 00:00 [received]
PHST- 2023/03/31 00:00 [revised]
PHST- 2023/04/05 00:00 [accepted]
PHST- 2023/05/15 19:13 [medline]
PHST- 2023/05/15 19:12 [pubmed]
PHST- 2023/05/15 13:46 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - cimb45040218 [pii]
AID - cimb-45-00218 [pii]
AID - 10.3390/cimb45040218 [doi]
PST - epublish
SO  - Curr Issues Mol Biol. 2023 Apr 11;45(4):3333-3346. doi: 10.3390/cimb45040218.